Abstract-Smooth muscle cells (SMCs) are a critical component of blood vessel walls that provide structural support, regulate vascular tone, and allow for vascular remodeling. These cells also exhibit a remarkable plasticity that contributes to vascular growth and repair but also to cardiovascular pathologies, including atherosclerosis, intimal hyperplasia and restenosis, aneurysm, and transplant vasculopathy. Mouse models have been an important tool for the study of SMC functions. The development of smooth muscle-expressing Cre-driver lines has allowed for exciting discoveries, including recent advances revealing the diversity of phenotypes derived from mature SMC transdifferentiation in vivo using inducible CreER T2 lines. We review SMC-targeting Cre lines driven by the Myh11, Tagln, and Acta2 promoters, including important technical considerations associated with these models. Limitations that can complicate study of the vasculature include expression in visceral SMCs leading to confounding phenotypes, and expression in multiple nonsmooth muscle cell types, such as Acta2-Cre expression in myofibroblasts. Notably, the frequently employed Tagln/SM22α-Cre driver expresses in the embryonic heart but can also confer expression in nonmuscular cells including perivascular adipocytes and their precursors, myeloid cells, and platelets, with important implications for interpretation of cardiovascular phenotypes. With new Cre-driver lines under development and the increasing use of fate mapping methods, we are entering an exciting new era in SMC research. Visual Overview-An online visual overview is available for this article. and was subsequently adapted for use in mammalian cells and mouse models. 6, 8 The Cre/lox site-specific recombination system is now well established for generation of conditional cell type-specific deletion or overexpression of specific genes, allowing for sophisticated mouse models in which to study cardiovascular disease. DNA regions flanked by loxP sites are often referred to as floxed. This Cre/lox system has been elegantly summarized in the prior article in this series on endothelialspecific Cre drivers. 9 An important variation in this technology is the fusion of Cre with a mutant estrogen receptor (Cre-ER T2 ) to allow tamoxifen-inducible cell type-specific gene expression or deletion. Feil et al 10 constructed 2 mutants of the ER that either contain G400V/M543A/L544A or G400V/L539A/L540A in their ligand binding domain. These 2 mutants are termed as T1 and T2, respectively. The T2 mutant version of ER is strongly activated by tamoxifen and has been widely used in mouse genetic studies. Tamoxifen treatment induces translocation of Cre-ER T2 from the cytosol to the nucleus where it can induce DNA recombination between 34 bp loxP sites.
Smooth Muscle Cells
Smooth muscle cells (SMCs) make up the muscular layer of arteries and veins and are essential in the regulation of vascular tone and blood pressure. Under physiological conditions, SMCs are differentiated and quiescent, but in response to injury, SMCs de-differentiate, characterized by proliferation, migration, and loss of contractile protein expression. Although the remarkable phenotypic plasticity of SMCs in the vessel wall is important for wound healing and growth, SMCs also play a role in pathophysiology. SMC de-differentiation is central to vascular pathologies such as atherosclerosis, restenosis, and aneurysms. 1, 2 Phenotypically modulated SMCs also contribute to the formation of fibrous cap, neointima, and foam cells in atherosclerotic plaques. 2 SMCs are integral to the vascular reactivity and remodeling changes that contribute to the pathophysiology of hypertension and its complications. 3 Thus, it is critical to elucidate the mechanisms by which SMCs are regulated.
Please see https://www.ahajournals.org/atvb/atvbfocus for all articles published in this series.
Differentiated SMCs are characterized by a large repertoire of genes encoding a variety of contractile/cytoskeletal proteins, including ACTA2 (α-smooth muscle actin), MYH11 (smooth muscle myosin heavy chain; formerly known as SM-MHC), CNN1 (calponin), TAGLN (transgelin; formerly known as SM22α), CALD1 (h-caldesmon), and SMTN (smoothelin). 4 These genes have been important markers in the study of SMC, and the regulatory regions of several of these genes have been used to drive expression of Cre recombinase. We will discuss the pros and cons of each in this review.
The Cre/lox System
The Cre/lox site-specific recombination system allows generation of cell-type specific and conditional deletion of a specific gene. Cre, a 38 kDa bacteriophage enzyme, has been shown to catalyze recombination between two 34 bp lox sites. 5 The Cre protein creates a DNA loop and then either excises or inverts the looped segment depending on the orientation of the loxP sites. 6, 7 Initially, the method was developed to function efficiently in yeast to cause recombination on chromosomes and was subsequently adapted for use in mammalian cells and mouse models. 6, 8 The Cre/lox site-specific recombination system is now well established for generation of conditional cell type-specific deletion or overexpression of specific genes, allowing for sophisticated mouse models in which to study cardiovascular disease. DNA regions flanked by loxP sites are often referred to as floxed. This Cre/lox system has been elegantly summarized in the prior article in this series on endothelialspecific Cre drivers. 9 An important variation in this technology is the fusion of Cre with a mutant estrogen receptor (Cre-ER T2 ) to allow tamoxifen-inducible cell type-specific gene expression or deletion. Feil et al 10 constructed 2 mutants of the ER that either contain G400V/M543A/L544A or G400V/L539A/L540A in their ligand binding domain. These 2 mutants are termed as T1 and T2, respectively. The T2 mutant version of ER is strongly activated by tamoxifen and has been widely used in mouse genetic studies. Tamoxifen treatment induces translocation of Cre-ER T2 from the cytosol to the nucleus where it can induce DNA recombination between 34 bp loxP sites. 11 As reviewed and highlighted in this review, a strategy that tends to yield faithful Cre expression involves inserting Cre recombinase into the gene of interest in a bacterial artificial chromosome (BAC) to express in mice. The limitations involve random site of integration and variable number of gene copies. Song et al 7 highlight the use of gene targeting by homologous recombination in embryonic stem cells or by using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) methods to ensure a single copy of a Cre recombinase gene is expressed from an endogenous gene locus. There are also now different types of recombinases and several variants of lox sites that can be used together to create more controlled recombination events. Song et al 7 elegantly describe breeding strategies to avoid unwanted recombination and methods to overcome such issues if they arise. Proper breeding strategies, genotyping protocols, and control experiments should help investigators in Cre-dependent gene manipulations and interpret their data appropriately.
There are additional general important considerations when using Cre/lox approaches. Several studies have highlighted the potential for differential sensitivities to Cre mediated recombination in distinct targeted floxed alleles. 12 Liu et al 12 investigated the recombination correlation between several floxed alleles induced by Cre-expressing mouse lines and determined that factors including potential methylation, distance between loxP sites, sequences flanking the loxP sites and the level of Cre activity per cell can contribute to differences in Cre-mediated recombination. Accordingly, investigators should carefully document the expression pattern of new Cre-driver mice with a reporter (lacZ [beta-galactosidase], mTmG [membrane Tomato, membrane green fluorescent protein], YFP [yellow fluorescent protein], etc). Similarly, the extent of recombination and degree of deletion should be evaluated using quantitative polymerase chain reaction or Southern blotting strategies. For inducible Cre lines, optimization of the timing and dosing of tamoxifen may be required. Additional important best practices include maintaining the Cre mice in a hemizygous manner (for transgenes) and as heterozygous (for Cre-knockin) to avoid problems such as mutagenesis or loss of endogenous gene function. Refreshing breeders periodically can also help minimize genetic drift, and periodic reevaluation of Cre patterns and deletion efficiency should be performed. Validating findings with multiple SMC Cre drivers, as was successfully employed by Herring et al 13 (see below in Myh11-Cre section), is an additional rigorous approach.
In reviewing the different approaches to generate Cre driver lines, it is apparent that fidelity in replicating endogenous gene expression patterns improves with larger promoter fragments, with enhanced recapitulation generally obtained from constructs generated from BAC segments or with knock-in of the Cre recombinase into the endogenous locus. Although these Cre-based strategies have opened new frontiers in SMC research, targeting Cre expression specifically to SMCs has proven challenging as many of these smooth muscle markers are expressed, at least transiently, in other cell types, including fibroblasts and myofibroblasts (detailed in following sections). Furthermore, expression of target genes in visceral smooth muscle can produce gastrointestinal phenotypes that complicate or preclude analysis of vascular phenotypes (discussed in the concluding section). Herein, we review smooth muscle-targeting Cre driver lines and highlight the advantages and caveats of each. We additionally summarize some of the recent paradigm-changing discoveries made possible by this technology.
Myh11-Cre
Of the aforementioned smooth muscle markers, MYH11 is widely considered the most specific for the smooth muscle lineage and the most definitive marker of SMC differentiation. Miano et al 14 were the first to report in situ hybridization analysis of Myh11 transcript expression and concluded that Myh11 was highly specific to SMCs in embryonic and adult mice. Subsequently, a transgene consisting of the 4.2 kb of the 5' flanking region of the rat Myh11 gene, 88 bp of the first exon (which is untranslated), an additional 11.5 kb of the first intron followed by the lacZ reporter gene was used to generate transgenic mice. 15 These Myh11-lacZ mice displayed specific transgene expression in vascular and nonvascular SMCs; however, there was wide variability in lacZ expression both within and between specific vessels. 15 Taking advantage 16, 17 Unfortunately, subsequent studies suggested that these Cre lines also induce recombination in the germline. 18, 19 More recently, a transgenic mouse carrying a Myh11-driven inducible Cre was generated through a distinct cloning strategy by the Offermanns group. 20 A fusion protein of the Cre recombinase with the modified ER binding domain (CreER
T2
) was cloned into the initial coding ATG codon of the mouse Myh11 gene carried by a BAC. 20 Tamoxifen treatment then promotes Cre-mediated-recombination and subsequent expression or excision of the target gene. 11 In their initial characterization of Myh11-CreER T2 mice also carrying the ROSA26R-lacZ reporter, 21 Wirth et al 20 reported inducible Cre-mediated betagalactosidase (β-Gal) activity exclusively in SMCs in the tissues examined, including in blood vessels in multiple organs and in stomach, colon, and bladder visceral SMCs. The use of the large genomic segment in the BAC likely confers this expression pattern replicating that of endogenous Myh11 with higher fidelity. It should be noted, however, that expression from this construct has not yet been thoroughly characterized during embryogenesis.
The Myh11-CreER T2 mice generated by the Offermanns lab are available from Jackson Laboratories (B6.FVB-Tg[Myh11-cre/ER T2 ]1Soff/J) and have proven to be a windfall for diverse studies evaluating the role of gene products in SMCs and the fate of SMCs during development and disease. 22 This Cre driver was used in 2 studies that determined that the majority of neointimal cells in models of vascular injury are derived from mature medial SMCs. These rigorous findings provided consensus in the field on the question of neointimal origin as the results were validated by 2 different labs using 2 distinct reporters (LacZ 13 and mTmG) 23 as well as 2 different injury models (femoral wire denudation 23 and carotid ligation 13 ). Furthermore, Herring et al 13 additionally confirmed the finding with the Acta2-CreER T2 (see later section for description of this Cre line).
Work from several laboratories has employed lineage tracing with the Myh11-CreER T2 line to uncover paradigm-shifting new roles for SMC in atherosclerosis. Gary Owens et al demonstrated that tamoxifen induction of Apoe
, and ROSA26R (YFP/YFP) mice results in efficient marking of medial SMCs in large arteries. Notably, their lineage tracing approach revealed that the contributions of SMCs to atherosclerotic plaques had been underestimated, as >80% of SMC-derived cells in plaques could not be identified by immunostaining for SMC contractile protein markers after high-fat diet feeding. 24 In plaques, mature YFP + SMC were found to have lost their classical SMC markers and express markers of other cell types, including macrophages or stem cells. 24 More recent work from the Greif lab found that preexisting SMCs are recruited into atherosclerotic plaques, first coating the cap of the plaque and subsequently invading the core. 25 Importantly, these investigations provide evidence that SMCs change fate during atherogenesis. Further mechanistic experiments, which include introducing a floxed allele for the Kruppel-like factor (klf) 4 into Myh11-CreER T2 lineage tracing mice, demonstrate that KLF4 plays a key role in pathological SMC transitions in atherosclerosis 24 as well as in cancer. 26 Fate mapping studies using the Acta-CreER T2 and Klf4 flox/flox mice also identified a key role for KLF4 in SMC transitions in pulmonary hypertension (see Acta2-Cre section below). 27 Although Myh11 transcript and the Myh11-CreER T2 transgene were originally reported to be specific to SMCs, data indicating expression in non-SMC populations are beginning to come to light in distinct contexts. For instance, the Greif lab recently showed that tamoxifen induction of Myh11-CreER T2 and ROSA26R
(mTmG/mTmG) mice also marked ACTA2 − cells in the alveoli of the adult lung. 28 In addition, hypoxia-induced alveolar ACTA2 + myofibroblasts express MYH11; indeed, in mice exposed to hypoxia (FiO 2 10%) for 21 days, ≈85% of alveolar ACTA2 + myofibroblasts express MYH11. 28 In a recent study from another group, the authors suggest that in the adult mouse lung, MYH11 is expressed in SMCs as well as at least a subset of pericytes and that these pericytes are YFP + in tamoxifeninduced Myh11-CreER T2 and ROSA26R (YFP/YFP) mice. 26 In the lungs of these mice, 10% of YFP + cells were found to be negative for MYH11. Although these may be derived from dedifferentiated pericytes or SMC, their origin is not definitively known. This study found that KLF4 upregulation also mediates phenotypic switching in YFP + perivascular cells, which contribute to a pro-metastatic microenvironment. 26 An important consideration is that the Myh11-CreER T2 transgene initially incorporated into the Y chromosome which has limited investigations with this transgene to male mice. This limitation is profound as SMCs are key players in cardiovascular development and disease, and cardiovascular disease is the leading cause of death in women. Notably, the laboratory of Zhihua Jiang recently reported that through breeding they have obtained a colony of Myh11-CreER T2 mice-presumably by translocation to the X chromosome-in which the transgene is inherited by both male and female mice. [29] [30] [31] Importantly, this colony may markedly enhance the study of SMCs in the development and disease of female mice.
Tagln-Cre
TAGLN, formerly known as SM22α, is an actin-binding protein that regulates SMC contraction and serves as a marker of the differentiated phenotype. Accordingly, Tagln/SM22α-Cre drivers have been commonly used to study smooth musclespecific expression. Although these were originally referred to and published as SM22α-Cre, we will refer to them in this review using the current official nomenclature Tagln-Cre. These Cre drivers have been widely employed despite the wellknown limitation that Tagln is transiently expressed in cardiac myocytes during embryonic development. By mid-gestation, Tagln gene expression becomes restricted to visceral and vascular SMCs. Olson et al 32 initially determined that a 455 bp fragment of the mouse SM22α promoter was sufficient to drive lacZ reporter activity in SMCs in vivo but did not completely recapitulate endogenous expression patterns. The first Tagln-Cre lines were made by the Feil group, using a transgenic or knock-in approach. The knock-in Tagln-Cre-ER T2 line was superior in recombination to the transgenic line, but efficiency was low in vascular SMC compared to visceral SMC. 33 Another early attempt created a transgenic Tagln-Cre with a 1.4 kb fragment of the Tagln promoter. 34 A ROSA26R-LacZ reporter indicated embryonic expression in heart, aorta,
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and umbilical vessels, but also in the head and tail regions of the embryo at E10.5. Conditional deletion of Srf with this Tagln-Cre proved to be embryonic lethal, identifying a key role for Srf in heart and vascular development. 34 The Liaw lab also took 2 approaches incorporating a 1.4 kb fragment of the Tagln promoter to make a transgenic Tagln-Cre and a Tet-on inducible Tagln-rtTA-Cre. When crossed to 5 reporter lines, these mice showed high variability in recombination. 35 An additional transgenic line was generated employing a longer 2.8 kb fragment of the mouse Tagln promoter to drive Cre expression. The Cre mRNA was detected at high levels in aorta, intestine, and uterus similar to endogenous Tagln. When crossed with ROSA-26R-lacZ reporter mice, efficient recombination was demonstrated in hepatic and pulmonary arteries, although nonmuscle cells in these organs did not express β-Gal. 36 This line (now congenic) is available from the Jackson Laboratories (B6.Cg-Tg[Tagln-cre]1Her/J) 36 and has been used by many investigators.
The Parmacek group used a similar strategy to construct Tagln-Cre using -2775 to +39 bp of the Tagln promoter which was similarly expressed in SMC during development and in adult tissues. 37 The expected expression was found in the vascular wall of cranial vessels, the bronchial arch arteries, umbilical artery as well as the developing heart at E9.5, and in adult vascular and visceral smooth muscle. Although arterial SMC was labeled with nearly 100% efficiency, as expression was also noted in the adult ventricular myocardium, this driver line did not faithfully recapitulate Tagln expression in the adult. 37 Chen et al 38 employed a distinct approach, knocking the Cre recombinase coding sequence into the endogenous Tagln locus in frame just before the Tagln initiation site (TaglnCre KI ). In this approach 2 targeted clones were injected into C57BL/6 blastocysts to produce chimeras, which were then further crossed with C57BL/6 female mice to generate heterozygous Tagln-Cre KI mice. A homozygous knockin of Cre may cause inadvertent deletion of endogenous gene. When crossed to ROSA26R LacZ or enhanced GFP (green fluorescent protein) reporter mice, expression from this Cre faithfully recapitulated expression of Tagln in adult tissues, including arteries, veins, bladder and gastrointestinal tract, with no expression in skeletal muscle. Strikingly, however, this TaglnCre KI did not drive expression in embryonic SMC or cardiac myocytes at E9-E16.5, but could be detected in neonates after birth. Although this does not mimic endogenous expression in this regard, this line could potentially circumvent adverse effects of gene expression changes driven by the Tagln-Cre during development. This line has also been available through Jackson Laboratories (B6.129S6-Tagln tm2(cre)Yec/J ) 38 and is widely published.
Nonsmooth Muscle Expression of Tagln
Some early studies that predated the development of TaglnCre lines detected Tagln expression in non-SMC or cardiac myocyte tissues. These include TAGLN expression in cultured human fetal lung myofibroblasts, 39 rabbit bladder serosal myofibroblasts, 40 and porcine adventitial myofibroblasts after vascular injury. 41 Subsequently, other studies have revealed that Tagln-Cre lines direct expression in other cell types. One study by Shen et al 42 used both Tagln-Cre lines available at Jackson Laboratories and bred them individually to a strain to transgenically express a DNMAML-GFP (dominant negative mastermind-like-GFP fusion protein ). This allowed use of GFP signal to trace cells labeled by each Cre, with the caveat of potentially confounding effects of overexpression of a factor that inhibits canonical Notch-mediated transcription on the pattern of GFP expression. Although GFP was detected in the expected SMC-rich tissues including aorta, bladder, stomach, and uterus, high expression was also noted in the immune cellrich spleen. Subsequent FACS (fluorescence-activated cell sorting) and labeling approaches revealed that the Tg(Taglncre)1Her/J line expressed in a portion of circulating neutrophils and monocytes. Genotyping for a recombined allele also revealed Cre activity in peripheral blood and peritoneal macrophages of the Chen lab Tgln2-Cre KI line. 42 Although this study is not definitive because of the introduction of DNMAML, it raised the provocative possibility that Tagln-Cre lines could drive expression in cells other than smooth muscle and cardiac myocytes. Work from other labs, including our own, discussed below, supports this notion.
Importantly, megakaryocytes, which give rise to platelets, also express TAGLN. 43 Diane Krause's lab noted that in mice with a tdTomato to GFP Cre-reporter (mTmG) 44 (Jax Gt[ROSA]26Sor tm4(ACTB-tdTomato,-EGFP)Luo /J), the Tagln-Cre transgene (Tg[Tagln-cre]1Her/J) causes from 30% to 60% of platelets to become GFP + . In Figure 1 , the tdTomato and GFP fluorescence of peripheral blood platelets is shown for wild type mice, mTmG mice without Cre recombinase and mTmG mice crossed with Tagln-Cre. Note that in the mouse with the Tagln-Cre, over half of the platelets in the peripheral blood are Tomato − and GFP + , indicative of Cre-mediated recombination in megakaryocytes. Thus, in mice with a gene of interest deleted using the Tagln-Cre, loss of gene expression in platelets could impact the phenotypes observed. This is particularly notable as this Cre driver is frequently used to study vascular SMC responses in models such as wire denudation to induce intimal hyperplasia, a process heavily influenced by platelets. Given the caveats of Tagln-Cre-driven expression in myeloid cells and platelets, bone marrow transplantation experiments would be an important approach to determine the extent to which observed phenotypes are attributable to SMC versus hematopoietic cells. Additionally, Varberg et al 45 recently demonstrated fetal Tagln expression in the vascular progenitor ECFCs (endothelial colony-forming cells). This study revealed that upregulation of Tagln in these ECFCs in response to gestational diabetes mellitus led to abnormalities in vasculogenesis, suggesting another potential factor to consider when using Tagln-Cre constructs in developmental studies.
Another notable Tagln expression pattern was uncovered when the Chen lab employed their Tagln-Cre knock-in line to delete PPAR-γ (peroxisome proliferator-activated receptorgamma) selectively in SMCs. The previously unappreciated expression of Tagln in a perivascular adipose precursor fortuitously led to exciting and unexpected observations because of a complete lack of development of perivascular adipose tissue (PVAT) in these mice. 46 PVAT was found to be highly similar to brown adipose tissue, demonstrating a thermogenic
Promoters to Study Vascular Smooth Muscle 607
effect to regulate intravascular temperature. PVAT was also revealed as an important source of prostacyclin such that loss of PVAT led to endothelial dysfunction. Another intriguing possibility generated by this study is the existence of a common precursor that gives rise to both PVAT and vascular SMC. Although off-target gene expression driven by the Tagln-Cre KI precluded a clear analysis of PPAR-γ function in SMC in this study, this unexpected Tagln expression pattern revealed multiple fascinating novel insights into the functions of PVAT and vascular homeostasis. Another intriguing and serendipitous discovery was made using the Talgn-Cre 36 to delete IKK-β (IκB kinase β) in SMC. The Tagln-Cre-IKKβ f/f (Tg[Tagln-cre]1Her/J) mice were resistant to atherosclerosis in the LDLR −/− (low-density lipoprotein receptor) background, but were surprisingly also found to be resistant to diet-induced obesity, hepatic steatosis, and exhibited improved glucose homeostasis. 47 Crossing the Talgn-Cre to Rosa26 EGFP revealed that Talgn-Cre is also active in primary adipose stromal vascular cells. 47 Interestingly, deficiency of IKKβ diminished the ability of these cells to differentiate, leading to accumulation of adipocyte precursor cells in adipose tissue, and revealed a mechanistic link between IKKβ and β-catenin. 47 Data from Kathleen Martin's lab reveal bright GFP expression in the aortic media in Tagln-Cre-mTmG reporter mice (Tg[Tagln-cre]1Her/J strain), as well as in the perivascular adipocytes (Figure 2) . It is now appreciated that adipose precursors reside in a perivascular niche. 48 The multiple studies mentioned herein suggest or directly indicate Tagln expression in adipogenic, vascular precursors as well as mature 
Acta2-Cre
ACTA2 is a key smooth muscle contractile protein whose expression increases with differentiation, but lower level expression is maintained even in synthetic phenotype SMC. Indeed, this marker is not a definitive marker of the smooth muscle lineage as it is expressed in many other cell types, most notably, fibroblasts and myofibroblasts. Multiple labs have generated Acta2-Cre lines. These have been primarily employed for the study of myofibroblasts and fibrosis, but under appropriate conditions, may have utility for SMC lineage tracing as described below. The first Acta2-Cre line was generated in 1996 using a 4.7 kb fragment of the human ACTA2 gene (−891 to +3828, containing promoter region, exon 1, intron 1, and 14 bp of exon 2). Crossing to a β-Gal reporter, they reported expression only in the heart, aorta, and diencephalon in early-stage embryos. 49 Another early Acta2-Cre line was developed by Wu et al 50 , using a fragment of the Acta2 gene spanning -1070 to +2582 bp including the first exon and part of first intron. When crossed to ROSA26R-LacZ, β-Gal expression was observed as expected in SMC-rich tissues including arteries, veins, and airways, and this reporter line was used to characterize mechanisms of bleomycin-induced pulmonary fibrosis.
Metzger et al 51 generated a transgenic tamoxifen-inducible Acta2-CreER T2 line using a large segment of the mouse Acta2 gene in a BAC. This construct was found to drive expression in both vascular and visceral smooth muscle with limited expression in cardiomyocytes. 51 This line (Tg[Acta2-cre/ER T2 ] Pcn) and has been the most used of all published Acta2-Cre drivers to date with at least 23 citations. The Greif laboratory has employed this line to study changes in the muscularization of lung arterioles in response to hypoxia, a model of the pathological hypermuscularization in pulmonary hypertension.
28 Acta2-CreER T2 and ROSA26R mTmG/mTmG mice were used to induce GFP labeling of mature SMCs in pulmonary arterioles. By assessing these vessels over a time course following hypoxia treatment, it was determined that GFP + Figure 2 . Tagln-Cre-mTmG labels the aortic media and perivascular adipose tissue. Confocal spinning disk microscopy of a section of aorta from a male Tagln-Cre-mTmG (Tg [Tagln-cre] 1Her/J) mouse that was immunostained with an antibody to mouse Adiponectin (Adipoq; No. 1119 R&D Systems, 1:10 dilution) and secondary antibody (Cy5, Cyan). Merged image at top left, individual channels for GFP, tdTomato, and Cyan also shown. Scale bar=50 mm. GFP (green fluorescent protein; green) indicates cells in which Tagln-Cre is active, whereas tdTomato (red) indicates cells in which there is no Cre-induced recombination. DAPI (4',6-diamidino-2-phenylindole; dark blue) staining indicates nuclei. A negative control with no secondary antibody is shown at bottom left. Note that adiponectin, a marker of differentiated adipocytes, strongly stains the perivascular adipocytes, as well as some medial SMCs (smooth muscle cells), which we have shown to express adiponectin.
vascular SMCs present in the normal adult were the source of nascent distal muscularization. 28 This study also made the surprising observation that the vast majority of alveolar myofibroblasts that arise in response to hypoxia are not derived from ACTA2 + cells. Conversely, the Myh11-Cre-ER T2 line crossed to ROSA26R mTmG/mTmG revealed that some GFP labeled cells near the lung arterioles lacked SMC markers in the absence of hypoxia. Thus, in this particular organ, vascular bed, and time point, Acta2-Cre-ER T2 was a more rigorous marker for SMCs than Myh11-Cre-ER
T2
. 27 Further studies using the Acta2-CreER T2 crossed to a multi-color reporter line (ROSA26R
Rainbow/+
) extended these pulmonary hypertension findings, revealing a clonal origin of SMCs in hypermuscularized distal arteriolar regions. 27 In addition to studies in pulmonary arteries, the Acta2-CreER T2 (Tg[Acta2-cre/ER T2 ]#Pcn) was used in a groundbreaking study assessing vasomotion in brain vessels. By comparing different Cre reporters and immunostaining approaches, it was determined that ACTA2 was expressed in arterioles but not in capillary-associated pericytes. In vivo, live imaging revealed that SMC but not pericyte constrictions are critical in pathological responses to brain ischemia. 52 The Acta2-CreER T2 , ROSA26R transgenic line was also used for lineage tracing in a recent study which noted that myoepithelial cells in the proximal trachea also express ACTA2. 53 Another transgenic Acta2-Cre line employing 5.2kb of the mouse Acta2 gene, including 2.4 kb of promoter as well as exon 1, intron 1, and part of exon 2, has been generated by the Kalluri lab. 54, 55 An Acta2-RFP (red fluorescent protein) reporter line demonstrated RFP expression in SMCs and rare interstitial cells in the kidney, 43 and the Acta2-Cre crossed to a YFP reporter was employed in a study of myofibroblasts in kidney fibrosis. 44 This Acta2-Cre (B6.FVB-Tg[Acta2-cre]1Rkl/J), backcrossed to C57BL/6J), 44 and the reporter line crossed to a reporter line to identify ACTA2 + mesenchymal progenitors within bone marrow and adipose tissue with osteogenic potential. Stappenbeck et al 57 used the BAC approach to generate an independent Acta2-CreER T2 line and crossed it to an mTmG reporter, generating strong GFP labeling of SMC in the gastrointestinal tract and demonstrating that loss of Acta2 gene expression in a mouse colonic injury model was due to SMC death as opposed to dedifferentiation.
Conclusions
In reviewing Cre driver lines used to study smooth muscle, we have noted that expression in non-SMCs is a common caveat which needs to be considered when designing and interpreting studies. Although all of the current SMC-targeting Cre driver lines have pros and cons, we highlight the need to select the most appropriate Cre for studies, depending on the processes one is attempting to model. Target organ biology, vascular bed, visceral SMC, and spatiotemporal considerations are all key variables to consider.
The Myh11-CreER T2 is currently regarded as the most specific for SMCs, yet expression in SMC-like cells, such as pericytes, have been noted in the lung. Platelet-derived growth factor receptor-β and neuron-glial 2 are well-known pericyte markers. However, these markers are also expressed in other cell types, including subsets of SMCs, thereby limiting the utility of mice carrying a Cre driven by the promoter of one of these genes. A Cre that specifically labels pericytes would be a major advancement for the field. Analysis of single-cell transcriptomic studies of pericytes is yielding candidate genes, and promoters of these genes will need to be assayed as to whether they can be used to specifically drive Cre expression in pericytes. 
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The Tagln-Cre lines, although widely used, are now appreciated to be expressed in cardiac myocytes, adipocytes, and their precursors in the vascular adventitia, megakaryoctyes, platelets, and myeloid cells. This complex expression pattern requires caution when evaluating phenotypes as these cell types may collectively influence cardiovascular physiology and pathophysiology through cardiometabolic and inflammatory effects. Bone marrow transplant, platelet transfusion, or complementary experiments employing myeloid-or platelettargeting Cre drivers are potential strategies to address myeloid and platelet contributions in Tagln-Cre mice. The perivascular adipose expression is more difficult to address. Murine PVAT transplants are challenging but may be a potential alternative in some models. 59 The Acta2-Cre lines strongly express in SMC but may be confounded by myofibroblast and stem cell expression. 56 Depending on the context, an Acta2-CreER T2 approach may have utility for the study of vascular 28, 52 or visceral 46 SMC as described above. A limitation to SMC-targeting Cre driver lines is the potential to label both vascular and visceral SMCs. When these tools are used to overexpress or delete genes that may cause a phenotype in nonvascular SMCs, there is potential for disruptive respiratory, genitourinary, and gastrointestinal complications that may preclude evaluation of the role of the gene in the vasculature. Examples include inducible deletion of Serum response factor (Srf) with the inducible Tagln-CreER T2 (Feil lab) which led to cachexia and death because of chronic intestinal pseudo-obstruction. 60, 61 Lethal gastrointestinal phenotypes were also observed with Myh11-CreER T2 -mediated deletion of Srf 62 or Dicer. 63 Promoters that distinguish between vascular and visceral, or arterial and venous SMC expression would be useful reagents for in vivo studies. An early transgenic lacZ reporter driven by 445 bp of the Tagln promoter was found to express in embryonic vascular smooth, cardiac, and skeletal muscle, but notably did not express in venous or visceral SMC. 32 A subsequent study identified the converse reagent using a 370 bp fragment of the telokin gene. This telokin construct was reported to be visceral-specific in vivo, whereas chimeras between this telokin sequence and the Tagln sequence were found to modulate the vascular versus visceral expression patterns. 64 A smooth muscle Cre driver line with preferential activity for vascular SMCs is currently under development (personal communication, Joe Miano). It is possible that additional SMC-specific or -restricted enhancers may be discovered as well, especially with the advent of genome-wide epigenetic investigations in SMC.
Some of the limitations associated with temporal patterns in Cre expression may be circumvented by using inducible constructs such as the Cre-ER T2 . For example, induction in adult mice could avoid the developmental expression of Tagln-Cre in the heart. The ability to induce recombination at a specific point in time is an essential hallmark of lineage tracing studies. The permanent marking and tracing of mature, differentiated SMCs with a Cre-driven reporter allows these cells to be identified as SMCs even after downregulating their classic contractile markers beyond detection. Although SMCs are well known to comprise fibrous caps, lineage tracing has identified key roles for SMCs in the initial formative processes of atherosclerotic lesions, 25 as well as their previously unappreciated role in giving rise to macrophage-like and stem cell-like cells. 24 This strategy also identified primed SMCs that are a source of hypermuscularization in pulmonary hypertension. 27, 28 Such fate-mapping approaches, when rigorously applied, will continue to expand our knowledge of the physiological consequences of SMC plasticity. 
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